This activity provides an overview of recent therapeutic advances for patients with newly diagnosed or relapsed multiple myeloma and the mechanisms by which novel therapies work.
This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.
Upon completion of this activity, participants should be better able to:
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
